pentobarbital will decrease the level or impact of elbasvir/grazoprevir by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. The therapeutic effect of elbasvir/grazoprevir could be reduced if coadministered with potent CYP3A inducers and is also as a result contraindicated.